Genzyme Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENZYME, and what generic alternatives to GENZYME drugs are available?
GENZYME has nine approved drugs.
There are six US patents protecting GENZYME drugs.
There are two hundred and one patent family members on GENZYME drugs in fifty countries and sixty-four supplementary protection certificates in seventeen countries.
Summary for Genzyme
International Patents: | 201 |
US Patents: | 6 |
Tradenames: | 8 |
Ingredients: | 8 |
NDAs: | 9 |
Patent Litigation for Genzyme: | See patent lawsuits for Genzyme |
Drugs and US Patents for Genzyme
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genzyme | RENAGEL | sevelamer hydrochloride | TABLET;ORAL | 021179-002 | Jul 12, 2000 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | AB | RX | Yes | Yes | 7,196,205 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Genzyme | CLOLAR | clofarabine | SOLUTION;INTRAVENOUS | 021673-001 | Dec 28, 2004 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | RX | Yes | No | 8,067,427 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-002 | Apr 6, 2011 | RX | Yes | Yes | 8,067,427 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Genzyme | RENAGEL | sevelamer hydrochloride | CAPSULE;ORAL | 020926-001 | Oct 30, 1998 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genzyme
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Genzyme | RENVELA | sevelamer carbonate | FOR SUSPENSION;ORAL | 022318-001 | Aug 12, 2009 | 6,858,203 | ⤷ Try a Trial |
Genzyme | RENVELA | sevelamer carbonate | FOR SUSPENSION;ORAL | 022318-002 | Feb 18, 2009 | 5,667,775 | ⤷ Try a Trial |
Genzyme | RENAGEL | sevelamer hydrochloride | TABLET;ORAL | 021179-002 | Jul 12, 2000 | 5,496,545 | ⤷ Try a Trial |
Genzyme | RENAGEL | sevelamer hydrochloride | TABLET;ORAL | 021179-001 | Jul 12, 2000 | 7,459,151 | ⤷ Try a Trial |
Genzyme | RENVELA | sevelamer carbonate | FOR SUSPENSION;ORAL | 022318-001 | Aug 12, 2009 | 7,459,151 | ⤷ Try a Trial |
Genzyme | RENAGEL | sevelamer hydrochloride | CAPSULE;ORAL | 020926-001 | Oct 30, 1998 | 6,509,013 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENZYME drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2008-12-04 |
➤ Subscribe | Injection | 1 mg/mL, 20 mL vial | ➤ Subscribe | 2012-02-23 |
➤ Subscribe | Tartrate Capsules | 84mg | ➤ Subscribe | 2018-08-20 |
➤ Subscribe | Tablets | 400 mg and 800 mg | ➤ Subscribe | 2008-05-22 |
➤ Subscribe | Powder for Oral Suspension | 0.8 g/packet and 2.4 g/packet | ➤ Subscribe | 2009-12-30 |
➤ Subscribe | Injection | 24 mg/1.2 mL vials (20 mg/mL) | ➤ Subscribe | 2012-12-17 |
International Patents for Genzyme Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2011066352 | ⤷ Try a Trial |
Brazil | 122015016313 | ⤷ Try a Trial |
Philippines | 12015502514 | ⤷ Try a Trial |
Slovenia | 2796457 | ⤷ Try a Trial |
Chile | 2016002589 | ⤷ Try a Trial |
Denmark | 3133070 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genzyme Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1409467 | 15C0036 | France | ⤷ Try a Trial | PRODUCT NAME: ELIGLUSTAT,EVENTUELLEMENT SOUS FORME D'UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
2371361 | 122019000082 | Germany | ⤷ Try a Trial | PRODUCT NAME: PLERIXAFOR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER EIN PHARMAZEUTISCH ANNEHMBARER METALLKOMPLEX DAVON; REGISTRATION NO/DATE: EU/1/09/537/001 20090731 |
1409467 | 37/2015 | Austria | ⤷ Try a Trial | PRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
1411918 | SPC/GB12/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; REGISTERED: UK EU/1/09/537/001 20090804 |
2371361 | 19C1058 | France | ⤷ Try a Trial | PRODUCT NAME: PLERIXAFOR OU SEL OU COMPLEXE METALLIQUE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/09/537/001 20090804; FIRST REGISTRATION: NL - EU/1/09/537/001 20090804 |
1244647 | SPC/GB12/036 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/749/001 20120217; UK EU/1/11/749/002 20120217 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.